Webinar Registration: Relentless Innovation of Multispecific Design
Alloy Therapeutics and Institute for Protein Innovation Announce Strategic Collaboration to Advance Next-Generation Antibody Discovery
Partnership combines world-class protein engineering with scalable drug development to accelerate innovation Boston — May 5, 2026 — Alloy Therapeutics, a leading biotechnology ecosystem company, today announced a strategic collaboration with the Institute for Protein Innovation (IPI), a nonprofit leader in protein engineering and in vitro discovery. Together, the organizations will create bespoke VHH (nanobody) […]
On-demand Webinar: From Data to Decisions in Antibody Discovery – Integrating AI/ML
Download our webinar on Data to Decisions in Antibody Discovery – Integrating AI/ML. Watch now Webinar Overview: In this webinar, Alloy will share practical, production-grade AI/ML workflows for candidate selection, developability triage, and optimization. We’ll cover what works today, what doesn’t, and how integrated data infrastructure and high-throughput make-test loops turn models into compounding advantage. […]
AI/ML in Antibody Discovery: What Works, What Doesn’t, What’s Next
Traditional antibody discovery is a war of attrition: screen thousands of candidates, fail late, and repeat. AI/ML changes that calculus by shifting failures from late and expensive to early and cheap. The result is fewer wet-lab cycles and a higher probability that the molecules you carry forward actually behave like drugs, while at the same time integrating learnings from failures at every stage.
From Data to Decisions in Antibody Discovery: Integrating AI/ML
WEBINAR Register for our upcoming webinar on integrating AI/ML workflows to drive smarter antibody selection, developability triage, and lead optimization. Tue, Mar. 31 | 11:00 AM EST Register Now Webinar Overview: AI/ML is reshaping antibody discovery, not by replacing the lab, but by making every wet-lab cycle smarter. In this webinar, Alloy will share practical, […]
Tahoe Therapeutics and Alloy Therapeutics to Form Joint Venture and Develop First-in-Class Antibody-Drug Conjugates for Hard-to-Treat Cancers
The new company combines Tahoe’s AI-powered target discovery engine with Alloy’s industry-leading ADC development capabilities to advance two first-in-class oncology programs built on deeply validated tumor targets.
Webinar: Unlocking Smarter Antibody Selection Strategies
Download our webinar on unlocking smarter antibody selection strategies to improve clinical success potential through integrated in vitro and in silico developability assessments. Watch now Webinar Overview: Many promising antibody therapeutics fail in development due to poor biophysical properties that can impact PK, stability, and manufacturability. This webinar presents an integrated strategy for early-stage developability […]
Overcoming challenging targets in antibody discovery
Webinar Overview: Unlock solutions for your most challenging targets with this webinar that demonstrates how Alloy Therapeutic’s precision approach to antibody discovery delivers results. This technical discussion explores: The power of hyperimmune mice: Benefit from ATX-GKH’s enhanced immune responses that produce higher serum titers and increased lymphoid cell output, especially valuable for high homology Streamline […]
Identify functional chimeric antigen receptors three months faster with Alloy’s end-to-end CAR discovery
Webinar overview: Looking for a way to accelerate your CAR-T therapeutic development projects? This presentation highlights how Alloy’s comprehensive platform and expertise can enable you to: Streamline end-to-end CAR discovery: Learn how Alloy’s full stack technologies enable discovery and screening of functional CARs with unprecedented speed and cost efficiency, overcoming limitations of conventional two-step processes. […]
Discover TCR mimic antibodies that Target Previously “Undruggable” Intracellular Proteins with Keyway™ TCR
Webinar Overview: Unlock access to intracellular protein targets and maximize TCRm/TCR-based therapeutic antibody discovery with this presentation by Dr. Dongxing Zha that reveals how Alloy’s proprietary Keyway™ TCRm Discovery Platform and expertise can: Overcome challenges to intracellular protein-targeted drug discovery: Learn how the Keyway™ TCRm Discovery Platform identifies TCR mimic (TCRm) antibodies that target intracellular […]